ISSN: 2279 - 0594

Available Online at www.jbpr.in

Journal of Biomedical and Pharmaceutical Research 2 (4) 2013, 31-41

REVIEW ARTICLE

RELEVANCE OF EPIGENOMICS IN THE MANAGEMENT OF CANCER

***Pramod Khatri[1], Madhulika Kabra[2]**

[1]Genetics Division, Department of Pediatrics, All India Institute of Medical Sciences, New Delhi 110029, India

[2]Professor of Pediatrics, Genetics Division, Department of Pediatrics, All India Institute of Medical Sciences, New Delhi 110029, India

Received 10 May 2013; Revised 28 May 2013; Accepted 20 June 2013

ABSTRACT

The recognizable proof of all epigenetic adjustments involved in gene expression is the succeeding stage for an improved comprehension of human biology in both typical and obsessive states. This field is implied as Epigenomics, and it is outlined as epigenetic changes (i.e., DNA methylation, histone modification and regulation by noncoding RNAs, for example microRNAs) on a genomic scale as opposed to a solitary gene. Epigenetics tweak the structure of the chromatin, subsequently influencing the translation of genes in the genome. Distinctive studies have recently distinguished changes in epigenetic changes in a couple of genes in particular pathways in cancers. In view of these epigenetic changes, drugs against distinctive sorts of tumors were produced, which fundamentally target epimutations in the genome. Examples incorporate DNA methylation inhibitors, histone modification inhibitors, and small molecules that target chromatin-renovating proteins. Then again, these medications are not particular, and reactions are a major issue; along these lines, new DNA sequencing innovations joined with Epigenomics tool have the possibility to recognize novel biomarkers and better molecular focuses to treat Cancer. The motivation behind this review is to talk over current and rising Epigenomics tools and to address how these new innovations might affect time to come of cancer management.

KEYWORDS: Genomics, Epigenomics, Epigenetics, DNA methylation, Histone modifications, Cancer Management

INTRODUCTION:

Sequencing the human genome stamped not the closure of the field of genomics, yet its starting. Researchers now stand in a novel position in the history of medicine to demarcate human malady, equipped with the innovative progressions and the information that has come about because of the Human Genome Project.[1,2] Using this informative data, a few advancement has recently been made to starting individualized and personalized medication, particularly for certain sorts of Cancer. Case in point, the launch of distinctive sorts of hereditary tests to foresee ailment (preventive medicine) and the development of the medication imatinib (Gleevec®) for blood tumors[3] were major achievements. Also, biomarkers that have the capacity to subgroup tumors dependent upon aggressivity, subsequently supporting in clinical choices, were additionally identified.[4] An exact molecular characterization of human tumors will permit an improved comprehension of the foundation for malady susceptibility and environmental impact, better determination and prediction, and the refinement of individualized medicine for optimal supportive tolerability.

Genomes from different people have recently been sequenced, [5, 6] permitting genomic examinations. Projects, for example the Hapmap[7] that distinguished varieties in the human genome, and ENCODE[8] that is investigating the utilitarian components in the genome, are assisting in the comprehension of complex illness phenotypes

Such ventures have the possibility to assist clarify the qualified data encoded by human genomes and support in the medication of cancer, for example Cancer. One of the principle issues in genomic science is grasping how gene expression is directed. To grasp the mechanism that are involved in gene regulation, the genes that are communicated in every cell sort of the form and how changes in their representation will sway in the expansion of cancer act for major challenges. What's more, environmental components, for example the presentation to synthetic compounds throughout life, smoking, and nourishment can decidedly influence and change the representation of genes.[9] Thus, in the post-genomic period, investigations of how human genes are managed and the mechanism that are ensnared in this methodology are of major criticalness for our comprehension of typical procedures and diseased states.

*Corresponding author: Pramod Khatri | Email: pramodsinghkhatri@gmail.com

Table 1: Drug developed using Epigenetics and Epigenomics tools.

Drug	mode of action	types of cancer
CP-4200 [3]	Molecule conjugated to lipid chain linked to azactidine that accelerates cellular uptake	Different type of cancer
S110 [3]	Modified and less toxic version of 5-aza-2-deoxycytidine DNA methyltransferase inhibitor	Different type of cancer
Dacogen [1] or Vidaza [2] and decitabine [2]	DNA methyltransferase inhibitor (5-azacytidine and 5 -aza-2-deoxycytidine)	Myelodysplastic syndrome and Hematological Malignancies ,test have started in solid tumors
Pyroxamide [2] (SAHA)	Histone deacetylases inhibitor	Hematological malignancies ,Prostate cancer , Bladder cancer , Neuroblastoma
RG108 [3]	Small molecule spe3cifically designed to bind and inhibit the active domain of DNA methyltransferase 1 enzyme	Different type of cancer
Entinostat [1] (MS-275)	Benzamide histone acetylase inhibitor	Blood and Lung tumors
DZNep [1](Deazaneplanocin A)	Histone methyltransferase inhibitor	Acute myeloid leukemia
siritinol and salermide [3]	SIRT1 protein inhibitor	Different types of cancer
Belinostat [1]	Histone deacetylases inhibitor	Hematological malignancies and solid tumors
Valproic acid [2] (Depakote)	Histone deacetylases inhibitor	Multiple myeloma ,Gliomas and Melanoma

Note: - [1]clinical trials ,[2] approved drug by FDA ,[3] under development

The informative content beyond the genome sequence was recently begat as the epigenome.[10] The Epigenome is described as the aggregation of alterations that can happen at a genomic level that won't change the grouping of the bases of the DNA yet can change the DNA conformity and, as a consequence, change the interpretation of genes. Epigenetics is the investigation of these changes in the DNA.[11] The accompanying are the essential epigenetic adjustments that happen in the DNA molecule:

1. coupling of diverse proteins to the DNA, for example histones and methyl-binding proteins,

2. expansion of compound groups in the bases of the DNA, for example methyl (CH3),

3. MicroRNAs and other noncoding RNAs that can direct the interpretation of genes through different systems.

While epigenetics has gathered more consideration, it is not another field, and concentrates on

dating from the 1980s have demonstrated the guarantee of utilizing pills that influence these components to treat cancer, particularly tumors.[12,13] In the final decade, we have been confronting an overpowering expand in medications influencing epigenetic mechanism that have been created to treat diverse sorts of cancer malignancy (see Table 1 and Figure 1). Illustrations are a developing number of DNA methylation inhibitors, histone modifications inhibitors, and small molecules that target chromatin-redesigning proteins. 5-Azacytidine was the first inhibitor of a catalyst involved in epigenetic alterations described.[14] This pill represses the DNA methyltransferase (DNMT) compound that is answerable for adding methyl aggregations to cytosine's found in both DNA and RNA molecules. An additional case of a DNMT inhibitor is 5-aza-2'-deoxycytidine, which is joined simply in the DNA molecule. The DNA methyltransferase covalently ties to these nucleotide analogs, and this sequestration influences its ordinary capacity. These mixes can additionally influence the way proteins ensnared in unit regulation have the capacity to tie to the DNA/RNA substrates. 5-Azacytidine was initially tried in myelodysplastic syndrome and leukemia, and it demonstrated promising results in patients with both Cancer.[15, 16] Since 5-azacytydine and other epigenetic pills are not exceptionally particular, symptoms are a major issue. A test confronted via researchers in this field is two-fold: design more specific pills and drugs that have fewer symptoms since they have a global impact in the epigenome of the cells. To conquer this issue, new DNA sequencing innovations (second and third era) joined together with Epigenomics apparatuses have developed. It is coming to be clear that these advances may expedite the distinguishing proof of better sub-molecular focuses for medication development and biomarker Identification for cancer management. In that respect, the essential reason for this survey is to talk about the rise of Epigenomics instruments determined from new DNA sequencing innovations and how they might influence the management of Cancer in near future.



Figure 1: Epigenomics and cancer treatment. Schematic representation of the three principle Epigenomics /epigenetic segments that are ensnared in gene expression control in human units (blue).

A few medications that are in current use, a work in progress, and in clinical trials for every epigenetic instrument of gene regulation are indicated in green. The medications put forth here are only a delegate record for every mechanism, and a few medications being worked on and in clinical trials at the minute are not demonstrated.

CANCER GENOMICS – PAST AND FUTURE:

Genomics is outlined as the investigation of whole genomes of organism, incorporating extra chromosomal DNA, for example the mitochondrial hereditary material. This field incorporates serious endeavors to figure out the whole DNA sequence of organism, utilizing fine-scale hereditary mapping and DNA sequencing with current and rising innovations. Interestingly, examining in the improvement of the pill trastuzumab (Herceptin®).[18] breast tumor patients that are HER2/neu (ErbB-2) positive have expanded survival rates when treated with this drug.[18]

One doubt that has risen after the sequencing of whole human genomes and examinations between them is 'what have we gained experience from sequencing human genomes?' It is clear that critical developments were created after the sequencing of the first human genome a decade prior. These progressions were principally connected to essential science, for example upgrades in DNA sequencing innovations, an abatement in the expense for sequencing the DNA molecule, and likewise the improvement of new methods to examine molecular changes in Cancer; for instance, there was an expansion in the amount of prescient and prognostic hereditary tests for tumors and different cancer. Interestingly, for connected pharmaceutical and patients, there have been a

disappointingly little number of medications and therapies that were discovered and advanced utilizing genomics instruments. Consequently, we have studied that the arrangement of human genomes is only a beginning stage to produce and collect the essential qualified information required for additional complex and deeper investigations.

In recent times, tumor genomes were sequenced and associated with normal cells for leukemia, breast, lung, and other tumor categories, utilizing second-generation DNA sequencing technologies.[19–25] The objective was to recognize transformations that could give rise to new biomarkers and new helps for these sorts of cancer malignancies. Furthermore, the 1000 Genome Project was recently launched[26] with the goal of sequencing the genome of thousand people in a small period of time. In parallel, associations are beginning to give entire genome sequencing services, with the point of comprehension the single's susceptibility for cancer, incorporating distinctive cancers.[27] accordingly; an impressive number of people will have their genomes sequenced in the years to come. Bit is this enough to comprehend how the human cell machinery works and to verify how Cancer or whatever viable ailment rolls out? It is likely that the engineering will be advantageous to genomic science in future clearing better approaches for approaching ailments, particularly Cancer. In spite of the fact that the genomic informative data will be of significance to distinguish transformations and other chromosomal anomalies, (i.e. insertions or deletion in the genomic DNA of disease cell), more studies will be indispensible to totally grasp human genomes. In this respect, the huge challenge will be to distinguish and catalog all the genes that are available in ordinary cells and their deformities (transformations, deletions, insertions, amplification, fusion proteins, and so on) in tumors. There is developing proof that Epigenomics will commit to this comprehension, and in the accompanying segments, I will talk over medications dependent upon epigenetic mechanism that are presently being used, in clinical trials, and a work in progress. Moreover, I will additionally talk about how this field could help in the improvement of better treatments for cancer malignancy and in the recognizable proof of new biomarkers.

EPIGENOMICS AND NEW TREATMENTS:

Epigenomics is coming to be more significant as the technologies for genome -wide epigenetic change investigation move forward. The best-known epigenetic marker is DNA methylation, and a few genes are described with this epigenetic change in distinctive tumor types.[28] DNA methylation happens in ordinary cells basically in locales that are intergenic, and loss of methylation (hypo methylation) in these regions was initially reported in the1980s.[29] Loss of DNA methylation or global hypo methylation is an early occurrence in tumor, and when it happens in dreary areas of the genome, the outcomes could be chromosomal instability, as formerly described.[30] On the other hand, increase of DNA methylation (hyper methylation) in the promoter area of distinctive genes can accelerate an abatement in the expression of this gene (otherwise called down regulation) and might be one of the foundations for Cancer development.[31] It is conjectured that DNA methylation might influence gene representation by blocking transcription after methyl-binding and different proteins form a multifaceted that hinders the entrance for transcription components to the gene promoter.[32] However, there are different models recommending that DNA methylation is the outcome rather than the explanation for gene inactivation.[33] In this case, imperfections in the transcription variables, for example mutation will leave promoter areas "opened" and more defenseless to the exploit of the DNMTs.[33] Consequently, these areas of the DNA will be methylated.[33]different genes are described as hyper methylated in the initiation and development of some sorts of tumors.[34]

The enzyme accountable for the control of DNA methylation in eukaryotic cells are the DNMTs.[35] There are three proteins recently depicted: DNMTs 1, 2, and 3. Nonetheless, DNMT1 may be the most imperative, particularly in ailments, for example cancer.[36] Different sorts of pills that target DNMTs have as of recently been produced. The thought behind utilizing a pill that hinders the proteins that control DNA methylation is that in tumor, there is an increment in their activity.[37] Drugs that chunk DNMTs incorporate 5-azacytidine, 5-aza-2′-deoxycytidine, modest molecule inhibitors, and others (see Table 1 for additional parts). 5-Azacytidine (Vidaza®) was endorsed by the Food and Drug Administration (FDA) since it expanded the survival of patients with myelodysplastic syndrome, and numerous patients on Vidaza came to be transfusion autonomous, demonstrating the potential for this sort of therapy.[38]

Histone imprints were recently portrayed as an essential epigenetic change to control gene interpretation in normal cells.[39] Histone changes, for example methylation, acetylation, ADP-ribosylation, ubiquitination, phosphorylation, and others, to histone tails modify chromatin structure. In any case, a complete comprehension of the exact molecular mechanism by which these adjustments to histone tails impact DNA-histone connections remains tricky. There are two

primary theory on how histone changes can influence chromosome capacity: 1) they may adjust the electrostatic charge of the histone, bringing about a structural change in histones or their coupling to DNA; or 2) these changes are binding destinations for protein recognition motif, for example the bromodomains or chromodomains, that distinguish acetylated lysine's or methylated lysine's, respectively.[40] The presence of these alterations and recognition motifs expedited the 'histone code' speculation proposed by Strahl and Allis.[41] .Overall, post-translational alterations of histones make an epigenetic mechanism for the regulation of a mixture of normal and malady identified procedures, incorporating Cancer. Drugs influencing histone adjustments have been developed and demonstrated assuring result about the medicine for diverse tumor types (see Table 1 for additional details).

In light of this learning, diverse sorts of histone deacetylases inhibitors, DNMT inhibitors, and small units that block enzymes that are embroiled in these epigenetic mechanism have been produced. What's more, joining together conventional therapies to pills that influence epigenetic mechanism is coming to be regular. For instance, clinical trials utilizing a blending of DNMT inhibitors with routine chemotherapy were generally tolerated in tumor patients and indicated empowering outcomes when contrasted and chemotherapy alone.[42]

Drugs focusing on chromatin and nucleosome renovating proteins are additionally an assuring restorative procedure to treat human Cancers (Table 1). Some of these proteins are deregulated in tumor, for example sirtuin 1 (SIRT1). It was recently indicated that focusing on this protein with pills, for example Salermide or Siritinol can expedite the reactivation of pro- apoptotic genes that are epigenetically stifled only in cancer cells.[43] These pills are additionally assuring as an anticancer agent, furnishing molecular proofs that SIRT1 may be included in human tumorigenesis.[43]

Chromatin-remodeling proteins are significant for proper gene articulation, and new drugs focusing on these proteins will be produced producing more adequate treatments against disease. All the Epigenetic/Epigenomics mechanisms and a portion of the pills that have been tried for Cancer treatments are denoted in Figure 1.

THE EFFECT OF NEW INNOVATIONS ON CANCER RESEARCH:

Second-era DNA sequencing innovations have been utilized to distinguish and catch hereditary and genomic changes in tumors when contrasted with normal units. In the Epigenomics field, these advances have been accommodating in recognizing locales of the DNA that are differentially methylated and have distinctive histone marks.[44] The Identification of proteins that are answerable for wrapping the nucleosome of tumor cells was additionally possible[44] (see Table 2). The advancement of new technology to study Cancer epigenomes will be pivotal for the distinguishing proof of deformities in tumor cells.

Thirty years back, sodium bisulfite was initially depicted as a reagent that could be utilized to catch DNA methylation in particular areas of the DNA.[45] This revelation has modernized the way we have been analyzing DNA methylation changes in cancer cell from distinctive tumor types.[45] This innovation permitted the dissections of particular regions of the DNA, the alleged gene-by-gene investigations (Table 2), to assess the rates of DNA methylation and correspond it to gene expression. Notwithstanding sodium bisulfite medication, absorption with methylation- sensitive restriction enzymes and numerous distinctive routines utilizing restriction enzymes joined with polymerase chain reaction[46] have been utilized for a long time. A few confinements of these systems incorporate the low number of dinucleotide CGs or CpGs that might be dissected at once (Table 2). Examinations of distinct genes or alternately locales of the DNA may likewise be connected to assess histone marks and nucleosome bundling, with the utilization of antibodies against particular marks in the histone proteins. These methods however are extremely difficult and limited to the region(s) of interest. Latest techniques were created for Epigenomics dissections, which can assess epigenetic changes on a global level in the genome of tumor cells (Table 2). Examples incorporate chromatin immunoprecipitation joined together with DNA sequencing (Chip–Seq) and high-throughput DNA methylation investigations after sodium bisulfite medication utilizing new DNA sequencing innovations (Table 2). Second-era DNA sequencing techniques are basically dependent upon pyro sequencing and emulsion polymerase chain response consolidated with beads that are implanted in slides with little pores (for additional qualified information on second-era DNA sequencing, see Table 2).

TABLE 2: Different types of technologies to uncover Epigenomics changes in cancer

Methods	Description	Examples
DNA methylation Arrays	Various DNA methylation array, such as array containing CG-rich region of DNA , whole genome arrays are also generated after bisulfite conversion of the DNA	CpG island specific arrays, whole genome bisulfide arrays
Third generation DNA sequencing	Methodology to be available soon based on nanotechnology, new method will decrease the cost of sequencing a genome in faster way than current technology.	SMRT ,Nano sequencing and other
ChiP -Seq technology	Specific antibodies used for histone binding to DNA allowed by DNA sequencing to map the location of histone protein in genome ,and their specific modification, second generation DNA sequencing has been used to uncover these changes	Chromatin immunoprecipitation combined with DNA sequencing
Gene -by -gene analyses	To evaluate methylation status of gene promoters. Technology based in sodium bisulfide treatment that converts unmethylated cytosine's to uracil by deamination .methylation changes are easily detected using this method after DNA sequencing, other methods include digestion with MSRE and antibodies against methyl-binding Proteins that can be used to detect specific methylation changes.	MSRE digestion ,bisulfite sequencing ,MSP ,MethyLight ,and other
ChiP-ChiP arrays	Specific antibodies used for histones binding to DNA followed by array hybridization ,Mainly used to identify regions that are active based on epigenetic modification	Chromatin immunoprecipitation combined with Microarray hybridization
Second generation DNA sequencing	Methodologies based on pyro sequencing and other technologies allowing the generation of huge amounts of genomic and trancriptomic data ,they have been also used to detect Epigenomics modification in human genomes.	Pyro sequencing ,sequencing by oligo Ligation and detection.

Abbreviations: ChiP ; chromatin immunoprecipitation, MSP ; methylation-specific PCR , MSRE; methylation-sensitive restriction enzymes, SMRT; single molecule real time PCR.

A wave of new sequencing innovations, named third era DNA sequencing, have been produced with the assurance of sequencing genomes, Transcriptome, and epigenomes speedier and with lower expenses. Some of these innovations are dependent upon the alleged Nano pores (Table 2). These pores are modest gaps that could be biotic or solid, in which the DNA can pass and be caught in a regulated manner.[47] These advances depend on the detection of single molecules, and naming of the sequencing substrate is some of the time needed. It is conceivable that these new sequencers developed utilizing nanotechnology could read long extends of DNA in a more excellent or equivalent route to the advances that are presently available. A latest report has showed that it is now conceivable to identify DNA methylation changes without the utilization of the reagent sodium bisulfite (which degrades the DNA and ordinarily requires high measures of starting material).[48] This is conceivable in a solitary molecule ongoing sequencing response with nanodetectors.48 It is coming to be clear that the new innovations being worked on will be of vitality for exploration in Epigenomics. This will have a positive effect on tumor research, expediting the Identification of new biomarkers and drug targets.

SUGGESTIONS FOR CANCER MANAGEMENT:

The stratification of patients dependent upon their tumor profile and/ or particular biomarkers is turning into the most ideal path to subgroup people with the same tumor aspects. This field is otherwise called personalized or individualized medication, and its target is to cohort the best medication for every particular patient or aggregation of patients. Personalized medicine includes the efficient utilization of sub-molecular information about every single patient to select or streamline protection and therapeutic care. These new methodologies are updating the path in which pharmaceutical associations attempt to recognize and test new Cancer medications. The thought of a blockbuster medication that could treat a wide range of tumor sorts has come to be improbable; tumor is a mind boggling illness and even a particular disease sort, for example breast cancer, and has a mixed bag of subclasses with totally diverse pathological and sub-molecular characteristics.

Epigenomics is a remarkable approach to cancer research since it can assist in the Identification of group of patients with the same epigenetic progressions and attributes in their tumors. The epigenetic pills utilized today are unspecific and have symptoms, for example the ones that happen in routine chemotherapy. This can shift from patient to patient, contingent upon the dose that is recommended. Imperatively, lower measurement medicines can lessen the reactions. The Identification of DNA methylation and histone adjustments connected with Cancer may have vital clinical utility in near future. The advancement of new innovation to uncover these progressions in a high-throughput style will have a major effect as talked over above and demonstrated in Tables 2 and 3.

Some progression in the field of epigenetics and Epigenomics has as of recently expedited the recognizable proof of particular bio-markers to manager the malady (see Table 3 for additional items). A mixed bag of genes have been portrayed as hyper methylated or alternately hypo methylated in Cancers, and this characteristic has demonstrated to some clinical importance in particular tumor types.[49,50] Genes, for example GSTP1, which is hyper methylated in a high percentage period characterized by prostate cancer, has been utilized as a biomarker for this ailment in body fluid and biopsy specimens.[51] what's more, assemblies of genes from the same pathway or alternately arrange have indicated the same epigenetic changes in tumors. Cases incorporate genes embroiled in cell adhesion, DNA repair, and apoptosis that might be down regulated by DNA methylation. Down regulation of genes connected with cell adhesion and relocation can build the danger of the tumor cells to metastasize to an auxiliary site in the body.[52, 53] for instance, adhesion molecule ADAM23 is remarkably methylated in breast tumors, and this characteristic is associated to metastases and a poor prediction in breast tumors.[54,55] A prototypal example of a DNA repair gene down regulated by DNA methylation is the MGMT gene, which is silenced by epigenetic mechanism in brain tumors.[56]

Tumors that don't express the gene MGMT are more delicate to radiotherapy and chemotherapy with temozolomide, and this sub-molecular characteristic has been utilized within clinical choices and ailment management for glioblastomas.[56, 57] Changes in the profile of histone modification have additionally been utilized to assess and maintain the danger of prostate cancer recurrence in patients.[58]

An additional aggregation of genes in which epigenetic progressions might be followed to operate cancer malignancy risk and movement is the microRNA (miR) gene family.[59] Some studies have recently indicated that miRs could be managed by epigenetic mechanism (Table 3). Changes in DNA methylation have been accounted for in particular cancer disease types for distinctive miRs.[60] Additionally, miRs are connected with vital embryonic gene pathways in cancer malignancy, and this association between embryonic advancement and tumor ought to be precisely examined for pill development in the future.[61] Since miRs direct hundreds to thousand

protein-coding genes by fragmented base-pairing,[62–64] permitting them to influence arranges and pathways of genes, it will be of significance to screen miRs interpretation changes intervened by epigenetics throughout tumor initiation and development.

Table 3: Some examples of epigenetic changes in a solitary gene or assembly of gene and their potential effect cancer medication.

Gene	Epigenetic/Epigenomic changes	Impact on cancer management
P16ink4A	Most common tumor suppressor inactivated by DNA methylation In tumor. Hyper methylation linked to poor outcome in Different cancer type.	Could be used as prognostic cancer marker
Histones	Differential histone modification such as acetylation ,methylation associated to cancer recurrence and worsen prognosis	Identifying the patient at more risk of recurrence of disease may help in treatment decision and better follow -up into the clinic
Apoptosis and cell cycle gene	Hyper methylation linked with poor outcome in various cancer types	Gene associated to apoptosis are hyper methylated in cancer , may be used as prognostic markers
miRNA	DNA methylation and histone modification of miRNA genes reported by different groups.	miRNA ,non coding gene regulating several proteins in cellular pathway, reexpression of miRNA in tumor impact for regulation of key gene in cells
Adhesion molecules (ADAM 33 ,ADAM 23 Cadherin's)	Hyper methylation in different cancer type and associated with cancer metastasis	Gene associated could be used as marker for disease progression
DNA repair gene (MGMT ,hMLh1 BRCA 1)	Hyper methylation of gene implicated in DNA repair ,help in identifying tumors, more susceptible to radiotherapies	Use of individual therapies could aid in patient outcome

Abbreviation : **ADAM23** ; A Disintegrin and Metalloprotease domain 23 , **ADAM 33** ; a Disintegrin and Metalloprotease domain 33, **BRCA1**; breast cancer gene 1 ,**MGMT**;O6 –methyltransferase ,**miRNA** ;micro RNA , **hMLH1** ;human mutl .homolog 1

On account of drug development and new treatments, it is likely that the future of epigenetic therapy will incorporate the utilization of various pills that exclusively have small impact in epigenetic hushing however that may be relied upon to have synergistic or alternately extra impacts when joined. Case in point, a latest study utilizing histone deacetylases inhibitors and high-dose chemotherapy both in vitro and in vivo demonstrated that this fusion may overcome chemo resistance, attain durable reduction, and enhance survival of patients with Burkitt lymphoma.[65] A major issue with the utilization of current epigenetic pills is that they are nonspecific and can reactivate genes arbitrarily. A concern is that they can make an entire genome hypo methylation, increment the amount of

chromosomal anomalies, influence the tumorigenic phenotype of cancer cell as beforehand described.[66, 67] However, it is confirmed that DNA methylation inhibitors act just in isolating cells, leaving non dividing cells unaffected, has as of recently been reported.[68] moreover, it appears that these medications motivate genes that have come to be anomalous in cancer.[69, 70]

Table 4 Examples of associations offering prescient epigenetic based test for Cancer diagnosis and screening.

Company	Epigenetic test	impact fro clinical decisions
Epigenomics AG	OncoSign and Epi proColon	Biomarker candidates used to identify drug response in cancer patient based DNA methylation analysis of gene. other epigenetic test offered for colon cancer management facilitating clinical decisions.
Exact Science	Stool-based DNA methylation analyses	company offers non invasive ,molecular screening technology for early detection of colorectal cancer using a combination of of DNA methylation markers ,stool -based DNA technology used for disease management
Sequenom	Cancer EpiPanels	The cancer EpiPanel contain targets of more than 400 cancer related gene . the Cancer EpiPanel can be used to produce Quantative DNA methylation profiles helping in tumor classification
Onco methylome sciences	MGMT methylation analysis	This test indicates if patient with unmethylated MGMT will benefit from addition of temozolomide to standard treatment of radiation therapy . Patient with methylated MGMT had longer progressions-free and overall survival with combination of radiation therapy and temozolomide .

The examination we confront today in the Epigenomics field connected to Cancer research is 'how to maintain cancer with the new advances and devices that are becoming to be available?' The new advances being worked on will expedite the Identification of better epigenetic markers and might support in the advancement of additional particular therapies. These medications will be centered in an aggregation of genes and not the whole epigenome (see Table 1 for epigenetic pills). The other investigation is 'what will be the effect of Epigenomics in the clinics?' In different expressions, how would we be able to interpret the revelations from basic science to the patient's bedside? In this respect, the FDA has as of recently affirmed a couple of epigenetic pills for distinctive tumor types, and some of these are extremely favorable (Table 1 and Figure 1). Molecular biomarkers, for example genes or aggregations of genes with progressions in epigenetic changes in tumors, have likewise been utilized to guide clinical choices. Examples are epigenetic changes in GSTP1 in prostate malignancy, p16ink4A in distinctive sorts of Cancer, and MGMT in brain tumors (see Table 3). There are associations (i.e., Onco methylome Sciences, Epigenomics AG, Sequenom, and others) recently offering a test with a board of epigenetic markers covering diverse genomic areas for Cancers (see Table 4 for additional functions). Recently, the company Exact Sciences released a combined test for four methylation markers for unanticipated recognition of colon disease with a 100% sensitivity. The preferences of utilizing epigenetic markers for unanticipated discovery of cancer malignancy and ailment management is that the test might be done in a minor tumor sample or even in body liquids, for example stool, blood, spinal fluid, and pee. Contingent upon the combo of markers acquired after the tests, clinicians have the ability to foresee the presence of the ailment and likewise bunch cancer malignancy patients based in tumor aggressiveness and other clinical characteristics, expediting clinical choices. Obviously, the effect of Epigenomics in

cancer malignancy management is relied upon to build with the appearance and advancement of new innovations.

CONCLUSIONS AND FUTURE DIRECTIONS:

In conclusion, the prospering fields of genomics and Epigenomics embody crucial features of modern Cancer exploration. The FDA has recently affirmed some epigenetic medications, and others are in clinical trials and being worked on, showing that this field recently influences the way we operate cancer malignancy. What's more, single genes and jamborees of genes from the same pathway have been distinguished as differentially methylated in cancer malignancies, and some have been utilized as molecular biomarkers in order to recognize patients with an improved or a more awful prognosis. Histone alteration changes have additionally been utilized as markers to screen Cancer patients. Obviously, epigenetic changes in tumors will influence the choices that are made in the clinics for the patients, particularly medication regimens and illness progression overseeing. Future direction incorporate the finding of new biomarkers and the development of additional effective pills against distinctive tumor types with the developing innovations and the development of new era of DNA sequencers. In view of the information talked over here, developing proof demonstrates that new Epigenomics devices will more and more influence the way we screen and administer cancer in near future.

ACKNOWLEDGMENTS:

The author acknowledges Dr Madhulika Kabra, Professor of Pediatrics, AIIMS Hospital for her critical help.

DISCLOSURE:

The author reports no conflicts of interest in this work

REFERENCES:

1. Venter JC, Adams MD, Myers EW, et al. The sequence of the human genome. *Science*. 2001;291(5507):1304–1351.
2. Lander ES, Linton LM, Birren B, et al. Initial sequencing and analyses of the human genome. *Nature*. 2001;409 (6822):860–921.
3. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. *N Engl J Med*. 2001;344 (14):1031–1037.
4. Lossos IS, Czerwinski DK, Alizadeh AA, et al. Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. *N Engl J Med*. 2004;350 (18):1828–1837.
5. Levy S, Sutton G, Ng PC, et al. The diploid genome sequence of an individual human *PLoS Biol*. 2007;5(10) :e254.
6. Wang J, Wang W, Li R, et al. The diploid genome sequence of an Asian individual. *Nature*. 2008;456 (7218):60 65.
7. International HapMap Consortium. A haplotype map of the human genome. *Nature*.2005;437(7063):1299–1320.
8. ENCODE Project Consortium. Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. *Nature*. 2007;447 (7146) :799–816.
9. López-Maury L, Marguerat S, Bähler J. Tuning gene expression to changing environments: from rapid responses to evolutionary adapta- tion. *Nat Rev Genet*. 2008;(8):583–593.
10. Callinan PA, Feinberg AP. The emerging science of epigenomics. *Hum Mol Genet*. 2006;15 Spec No 1:R95–R101.
11. Esteller M. Epigenetics in cancer. *N Engl J Med*. 2008;358(11):1148–1159.
12. Wilson VL, Jones PA, Momparler RL. Inhibition of DNA methyla - tion in L1210 leukemic cells by 5-aza- 2'-deoxycytidine as a possible mechanism of chemother-apeutic action. *Cancer Res*. 1983;43(8):3493–3496.
13. Jones PA. Altering gene expression with 5-azacytidine. *Cell*. 1985; 40(3):485–486.
14. Jones PA, Taylor SM. Cellular differentiation, cytidine analogs and DNA methylation. *Cell*. 1980;20(1):85–93.
15. Pinto A, Zagonel V. 5-Aza-2'-deoxycytidine (Decitabine) and 5-azacy- tidine in the treatment of acute myeloid leukemias and myelodysplastic syndromes: past, present and future trends. *Leukemia*. 1993;7 Suppl 1:51–60.
16. Karon M, Sieger L, Leimbrock S, et al. 5-Azacytidine: a new active agent for the treatment of acute leukemia. *Blood*. 1973;42(3):359–365.
17. Slamon DJ, Godolphin W, Jones LA. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. *Science*. 1989; 244(4905):707–712.
18. Paik S, Kim C, Wolmark N. HER2 status and benefit from adju- vant trastuzumab in breast cancer. *N Engl J Med*. 2008;358(13): 1409–1411.
19. Ley TJ, Mardis ER, Ding L, et al. DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. *Nature*. 2008;456(7218): 66–72.
20. Stephens PJ, McBride DJ, Lin ML, et al. Complex landscapes of somatic rearrangement in human

breast cancer genomes. *Nature*. 2009;462 (7276): 1005–1010.

21. Lee W, Jiang Z, Liu J, et al. The mutation spectrum revealed by paired genome sequences from a lung cancer patient. *Nature*. 2010; 465(7297):473–477.

22. Pleasance ED, Stephens PJ, O'Meara S, et al. A small-cell lung cancer genome with complex signatures of tobacco exposure. *Nature*. 2010; 463(7278):184–190.

23. Pleasance ED, Cheetham RK, Stephens PJ, et al. A comprehensive catalogue of somatic mutations from a human cancer genome. *Nature*. 2010;463(7278):191–196.

24. Beroukhim R, Mermel CH, Porter D, et al. The landscape of somatic copy-number alteration across human cancers. *Nature*. 2010; 463(7283):899–905.

25. Dalgliesh GL, Furge K, Greenman C, et al. Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. *Nature*. 2010;463(7279):360–363.

26. Butler D. Human genome at ten: science after the sequence. *Nature*. 2010;465(7301):1000–1001.

27. Kaye J. The regulation of direct-to-consumer genetic tests. *Hum Mol Genet*. 2008;17(R2):R180–R183.

28. Esteller M. Epigenetic gene silencing in cancer: the DNA hypermethylome. *Hum Mol Genet*. 2007;16 Spec No 1:R50–R59.

29. Feinberg AP, Vogelstein B. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. *Nature*. 1983;301 (5895) :89–92.

30. Costa FF, Paixão VA, Cavalher FP, et al. SATR-1 hypomethylation is a common and early event in breast cancer. *Cancer Genet Cytogenet*.2006; 165(2) :135–143.

31. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. *Nat Rev Genet*. 2002;3 (6):415–428.

32. Esteller M. Cancer epigenomics: DNA methylomes and histone- modification maps. *Nat Rev Genet* 2007;8 (4):286–298.

33. Turker MS. Gene silencing in mammalian cells and the spread of DNA methylation. *Oncogene*. 2002;21 (35) :5388–5393.

34. Jones PA, Baylin SB. The epigenomics of cancer. *Cell*. 2007;128 (4): 683–692.

35. Bestor TH. The DNA methyltransferases of mammals. *Hum Mol Genet*. 2000;9(16):2395–2402.

36. Robertson KD. DNA methylation, methyltransferases, and cancer. *Oncogene*. 2001;20(24):3139–3155.

